Theron Pharmaceuticals, founded in 2008, is a privately held biotechnology company based in Sunnyvale, CA. They specialize in developing a best-in-class, long-acting M3 muscarinic antagonist (LAMA) for the improved treatment of chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD) and severe asthma. Their lead development candidate, TRN-157, represents a major commercial opportunity as it promises to deliver the superb clinical pharmacology of tiotropium, the current standard-of-care for COPD, while also offering the ability to be combined with other drugs and used in various inhalation devices. Theron Pharmaceuticals aims to simplify disease management and improve clinical outcomes for COPD and severe asthma patients through the development of differentiated once-a-day combination therapies.Generated from the website